Exelixis

YTD

ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,147

Employees1,147

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,147

Employees1,147

EXEL Key Statistics

Market cap

11.78B

Market cap11.78B

Price-Earnings ratio

17.84

Price-Earnings ratio17.84

Dividend yield

—

Dividend yield—

Average volume

2.80M

Average volume2.80M

High today

$44.20

High today$44.20

Low today

$42.75

Low today$42.75

Open price

$42.75

Open price$42.75

Volume

3.36M

Volume3.36M

52 Week high

$49.62

52 Week high$49.62

52 Week low

$32.38

52 Week low$32.38

Stock Snapshot

The current Exelixis(EXEL) stock price is $43.75, with a market capitalization of 11.78B. The stock trades at a price-to-earnings (P/E) ratio of 17.84.

On 2026-02-07, Exelixis(EXEL) stock moved within a range of $42.75 to $44.20. With shares now at $43.75, the stock is trading +2.3% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 3.36M, compared to an average daily volume of 2.8M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $32.38.

EXEL News

Simply Wall St 11h

FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test

FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data...

TipRanks 3d

Exelixis price target raised to $44 from $41 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on Exelixis (EXEL) to $44 from $41 and keeps an Equal Weight rating on the shares as part of a Q4 e...

Simply Wall St 3d

Assessing Exelixis Valuation After FDA Accepts Zanzalintinib NDA In Metastatic Colorectal Cancer

Exelixis (EXEL) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for zanzalintinib plus atezolizumab in previously...

Analyst ratings

50%

of 22 ratings

Buy

45.5%

Hold

50%

Sell

4.5%

More EXEL News

TipRanks 4d

Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target on Multi-Tumor Commercial Potential

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Exelixis today and set a price target of $52.00. Claim 50% Off TipRanks Premium Unlock hedge fun...

TipRanks 5d

Exelixis reports zanzalintinib new drug application accepted for review by FDA

Exelixis (EXEL) announced that its new drug application for zanzalintinib, in combination with atezolizumab, has been accepted for review in the U.S. for the tr...

Simply Wall St 6d

Is Exelixis Using Zanzalintinib To Quietly Redefine Its Post-Cabometyx Strategy?

Exelixis recently submitted a US FDA application for its next-generation cancer drug zanzalintinib, seeking approval in combination with Roche’s Tecentriq for p...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.